Prostate cancer is increasingly becoming a significant health concern in China that poses various challenges in the management and treatment of this disease.
A comprehensive consensus was developed, aimed at addressing critical gaps in prostate cancer management, covering the stages of screening, treatment, and follow-up care for patients throughout China.
The consensus was published in the journal UroPrecision on 10th Oct 2024, focusing on 19 pivotal questions, covering various aspects of prostate cancer management.
The consensus highlights the importance of early detection in combating the disease, with 89% of the participating experts underscoring the efficacy of PSA screening in reducing prostate cancer-specific mortality rates.
The consensus advocates for the incorporation of next-generation hormonal agents in combination with androgen deprivation therapy (ADT) to tackle the aggressive nature of metastatic forms of the disease.
75% of experts concurred that additional assessments should be pursued in cases where standard imaging fails to reveal metastasis.
The consensus recommends initiating PSA screening at the age of 50 for men who do not have a family history of prostate cancer or carry BRCA2 mutations.
The recommendations aim to foster a more structured approach to managing prostate cancer, ensuring healthcare professionals are equipped with knowledge to confront prostate cancer effectively.
This consensus could serve as a vital instrument in fighting against this growing health threat, paving the way for improved care and treatment methodologies that could ultimately reduce the burden of the disease.
The consensus published in UroPrecision marks a crucial advance in prostate cancer management in China, aimed at improving patient care and addressing the immediate needs of those affected by prostate cancer.